PT  - JOURNAL ARTICLE
AU  - Nisreen M.A. Okba
AU  - Marcel A. Müller
AU  - Wentao Li
AU  - Chunyan Wang
AU  - Corine H. GeurtsvanKessel
AU  - Victor M. Corman
AU  - Mart M. Lamers
AU  - Reina S. Sikkema
AU  - Erwin de Bruin
AU  - Felicity D. Chandler
AU  - Yazdan Yazdanpanah
AU  - Quentin Le Hingrat
AU  - Diane Descamps
AU  - Nadhira Houhou-Fidouh
AU  - Chantal B. E. M. Reusken
AU  - Berend-Jan Bosch
AU  - Christian Drosten
AU  - Marion P.G. Koopmans
AU  - Bart L. Haagmans
TI  - SARS-CoV-2 specific antibody responses in COVID-19 patients
AID  - 10.1101/2020.03.18.20038059
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.18.20038059
4099  - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038059.short
4100  - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038059.full
AB  - A new coronavirus, SARS-CoV-2, has recently emerged to cause a human pandemic. Whereas molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are important for contact tracing, identifying the viral reservoir and epidemiological studies. Here, we developed serological assays for the detection of SARS-CoV-2 neutralizing, spike- and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed infections of SARS-CoV-2, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrate that most PCR-confirmed SARS-CoV-2 infected individuals seroconverted, as revealed by sensitive and specific in-house ELISAs. We found that commercial S1 IgG or IgA ELISAs were of lower specificity while sensitivity varied between the two, with IgA showing higher sensitivity. Overall, the validated assays described here can be instrumental for the detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiological and vaccine evaluation studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Zoonoses Anticipation and Preparedness Initiative (ZAPI project; IMI grant agreement no. 115760), with the assistance and financial support of IMI and the European Commission, in-kind contributions from EFPIA partners.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available form corresponding authors upon reasonable request.